
Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Christopher Topoleski, who is the Director of Federal Legislative Affairs for ASHP, discusses the ongoing legislative efforts targeting drug prices and what to expect moving forward.

Mark Eastham, BS, RPh, Senior Vice President of McKesson RxO, discusses the growth of specialty pharmacy in the health system space.

Phase 2 data show positive results for a therapy including 2 immune checkpoint inhibitors and chemotherapy.

Top news of the day from across the health care landscape.

Early detection is vital to more patients with hepatitis C virus being eligible for increasingly efficient direct-acting antiviral treatment options.

At the 2018 ASHP Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, offered advice on how pharmacy providers can work to overcome biosimilar reimbursement challenges and encourage biosimilar adoption.

In this clip, Christopher Topoleski, Director of Federal Legislative Affairs for the American Society of Health-System Pharmacists (ASHP), talks about how the legislative landscape of the 340B Drug Pricing Program has evolved and what's to come.

Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

The 2018 ASHP Midyear Clinical Meeting got off to a magical start today when basketball legend, businessman, and HIV/AIDS advocate Earvin “Magic†Johnson delivered the keynote address at the convention’s opening session.

The ASHP Award for Distinguished Leadership recognizes individuals who have achieved excellence in pharmacy practice leadership.

A phase 2 study demonstrated promising response rates and overall survival in patients with acute myeloid leukemia who were treated with azacitidine plus nivolumab.

Abeparvovec (Zolgensma) is a one-time infusion that replaces the defective or missing SMN1 gene with a functional copy that can create the SMN protein and prevent the loss of motor neurons in patients with spinal muscular atrophy.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Some of the oldest and most important drugs have suddenly been subject to very short supplies.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, gives an overview of the challenges associated with hemophilia management.

The American Society of Health-System Pharmacists (ASHP) kicked off its annual Midyear Clinical Meeting and Exhibition this Saturday in Anaheim, California.

Technological advances have widened the potential solutions to improve adherence to high-cost specialty drugs.

Top news of the day from across the health care landscape.

It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.

Epstein-Barr virus and Kaposi's sarcoma herpesvirus can activate and lead to the growth of cancerous cells.

Top news of the day from across the health care landscape.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.

The drug’s application was designated for fast track and priority review, as well as orphan product status.

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018 thus far.